LifeArc

Tribune Therapeutics is a preclinical biopharmaceutical company dedicated to developing innovative medicines for the treatment of various fibrotic diseases. The company focuses on creating therapies that target the CCN protein family, a group of signaling proteins that play a crucial role in the development of fibrosis. By concentrating on these specific proteins, Tribune Therapeutics aims to provide effective treatment options for patients suffering from fibrotic conditions.

Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

Ikarovec is a gene therapy company focused on developing early-stage assets for the treatment of common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, including dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By targeting these conditions, Ikarovec seeks to provide effective treatments that restore sight and prevent blindness in patients.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

Affect Therapeutics operates a digital treatment platform designed to address drug and alcohol addiction through a mobile application. The company offers an integrated program for various substance use disorders, utilizing contingency management and reward systems to engage users and promote retention. By providing financial incentives, the platform encourages patients to adopt healthier behaviors and establish new habits, ultimately aiming to improve outcomes for individuals seeking to overcome addiction.

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.

Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.

Surgery Hero is a pioneering digital prehabilitation clinic focused on helping individuals prepare for and recover from surgery in the comfort of their homes. By optimizing both physical and mental health prior to surgical procedures, the platform aims to reduce the risk of complications and enhance recovery. Through a combination of expert health coaches and digital guidance, Surgery Hero provides members with the necessary tools and lifestyle habits that have been shown to improve surgical outcomes. This innovative approach allows patients to effectively prepare for surgery and ensures a safer recovery process.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on developing innovative solutions that combine prescription drugs with digital therapies. Founded by a team of experienced healthcare professionals and life scientists, the company aims to optimize medication dosing through real-time feedback and linked behavioral therapy to enhance patient outcomes. Currently, Closed Loop Medicine is developing products targeting hypertension and insomnia, alongside a diverse pipeline addressing various chronic diseases. The company prioritizes the needs of both patients and clinicians in the design and development of its offerings, striving to integrate technology effectively within the healthcare system.

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that specializes in developing therapeutic drugs for hyperexcitability disorders affecting the nervous system. Founded in 2018, the company focuses on creating innovative treatments for conditions such as chronic pain, depression, epilepsy, and anxiety, which significantly impact millions of individuals. Eliem utilizes its expertise in neuroscience and translational medicine to advance a promising pipeline of drug candidates, including its lead candidate, ETX-155, aimed at addressing major depressive disorder and focal onset seizures. The company's mission centers on meeting unmet medical needs and improving patients' quality of life through its novel therapies.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, focuses on the design and discovery of novel therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company specializes in developing innovative therapeutics aimed at treating chronic inflammatory diseases, utilizing breakthrough technology to create first-in-class antibodies against challenging disease targets. By isolating high-quality antibodies against complex protein targets that have previously proven difficult for drug discovery, DJS Antibodies aims to provide effective treatments for conditions that are currently undruggable and untreatable.

BrainWaveBank Limited is a brain health research company focused on developing innovative solutions to track and improve cognitive health, particularly in the context of dementia. Founded in 2015 and based in Belfast, United Kingdom, the company has created a unique wearable electroencephalography (EEG) device that allows users to non-invasively measure their brain activity. This device works in conjunction with mobile games designed to challenge cognitive skills, enabling individuals to monitor their cognitive health daily from the comfort of their homes. By securely collecting and analyzing data from a large user base, BrainWaveBank aims to build comprehensive neurocognitive profiles that can advance the understanding of brain health and inform the development of future treatments for neurological disorders. The company's approach emphasizes scalability and accessibility, making it a valuable tool for both consumers and clinical professionals.

Brightlobe Limited, founded in 2012 and based in London, develops tablet games aimed at supporting children's growth and development, particularly for those with chronic illnesses. The company is pioneering a game-based platform that integrates a new system for healthcare, focusing on early detection of pediatric autism and ADHD, currently undergoing Phase 2 clinical trials in the US and UK. Brightlobe's platform serves as a collaborative tool for parents, teachers, and healthcare professionals, facilitating the monitoring of a child's development. The team comprises experts in game design, machine learning, and cognitive neuroscience, ensuring a robust approach to integrating educational and developmental support within their gaming products.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

PolyProx Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. It focuses on researching and developing innovative drug therapies aimed at treating cancer and neurodegenerative diseases. The company's flagship product, Polyproxin, utilizes engineered proteins that selectively target tumor cells. This mechanism activates the natural degradation processes within the cells, allowing for the removal of disease-causing proteins. By employing this novel approach, PolyProx aims to provide effective treatment options for cancer patients, potentially improving their outcomes and quality of life.

Ikarovec is a gene therapy company focused on developing early-stage assets for the treatment of common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, including dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By targeting these conditions, Ikarovec seeks to provide effective treatments that restore sight and prevent blindness in patients.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

AMR Centre Limited is focused on addressing the challenge of antimicrobial resistance through the development of new antibiotics. Established in 2016 and located in Macclesfield, United Kingdom, the company offers development services to organizations globally, partnering with them to expedite the creation of innovative antibiotic solutions. In return for these services, AMR Centre receives a commercial share from the newly developed products. Through its efforts, the company aims to contribute significantly to the fight against drug-resistant infections, improving healthcare outcomes worldwide.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.